Lessons From Bluebird Bio: How To Launch Advanced Therapies in Germany

 
• By Francesca Bruce

Outcomes-based deals are important for launching cell and gene therapies in Germany, but bluebird bio’s painful experience with Zynteglo shows the importance of the taking the right approach to ensure market success.

German Flag and Map
Zynteglo experience offers lessons on launching ATMPs in Germany • Source: Alamy

More from Gene Therapies

More from Advanced Therapies